Purpose
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors
Full Title
A Phase 1/2 Dose escalation and dose expansion study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
ClinicalTrials.Gov ID
NCT03425279
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.